Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Genmab A/S Sponsored ADR (GMAB : NSDQ)
 
 • Company Description   
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.

Number of Employees: 1,212

 
 • Price / Volume Information   
Yesterday's Closing Price: $30.43 Daily Weekly Monthly
20 Day Moving Average: 777,489 shares
Shares Outstanding: 657.34 (millions)
Market Capitalization: $20,002.90 (millions)
Beta: 0.98
52 Week High: $49.07
52 Week Low: $27.42
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -18.81% -8.55%
12 Week -6.31% 3.01%
Year To Date -23.08% -6.01%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
KALVEBOD BRYGGE 43
-
COPENHAGEN,G7 1560
DNK
ph: 45-7020-2728
fax: -
acn@genmab.com http://www.genmab.com
 
 • General Corporate Information   
Officers
Jan G. J. van de Winkel - President & Chief Executive Officer
Anthony Mancini - Executive Vice President and Chief Operating Offic
Anthony Pagano - Executive Vice President and Chief Financial Offic
Judith Klimovsky - Executive Vice President
Birgitte Stephensen - Senior Vice President

Peer Information
Genmab A/S Sponsored ADR (CORR.)
Genmab A/S Sponsored ADR (RSPI)
Genmab A/S Sponsored ADR (CGXP)
Genmab A/S Sponsored ADR (BGEN)
Genmab A/S Sponsored ADR (GTBP)
Genmab A/S Sponsored ADR (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 372303206
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 657.34
Most Recent Split Date: (:1)
Beta: 0.98
Market Capitalization: $20,002.90 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.21 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.88 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 26.56% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 34.63
Trailing 12 Months: 53.39
PEG Ratio: 1.30
Price Ratios
Price/Book: 5.84
Price/Cash Flow: 38.61
Price / Sales: 14.21
EPS Growth
vs. Year Ago Period: -59.26%
vs. Previous Quarter: -35.29%
Sales Growth
vs. Year Ago Period: 24.70%
vs. Previous Quarter: -20.66%
ROE
03/31/22 - 10.90
12/31/21 - 14.23
09/30/21 - 14.37
ROA
03/31/22 - 9.81
12/31/21 - 12.79
09/30/21 - 12.92
Current Ratio
03/31/22 - 17.31
12/31/21 - 14.50
09/30/21 - 12.00
Quick Ratio
03/31/22 - 17.31
12/31/21 - 14.50
09/30/21 - 12.00
Operating Margin
03/31/22 - 26.34
12/31/21 - 35.58
09/30/21 - 36.35
Net Margin
03/31/22 - 26.34
12/31/21 - 35.58
09/30/21 - 36.35
Pre-Tax Margin
03/31/22 - 35.17
12/31/21 - 46.96
09/30/21 - 46.68
Book Value
03/31/22 - 5.21
12/31/21 - 5.37
09/30/21 - 5.14
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©